Gain Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GANX Nasdaq 2836 gaintherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gain Therapeutics, Inc.

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week - Jan 7th, 2026 5:00 am
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 - Jan 6th, 2026 5:00 am
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why - Dec 22nd, 2025 10:00 am
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease - Dec 18th, 2025 2:05 pm
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease - Dec 18th, 2025 5:00 am
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy - Dec 8th, 2025 10:00 am
Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug Development - Nov 28th, 2025 11:26 pm
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 - Nov 20th, 2025 5:00 am
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know - Nov 17th, 2025 10:00 am
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update - Nov 12th, 2025 5:00 am
Gain Therapeutics to Present at Neuroscience 2025 - Oct 30th, 2025 5:00 am
Gain Therapeutics to Attend the 2025 Maxim Growth Summit - Oct 16th, 2025 5:00 am
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders® - Oct 6th, 2025 6:15 am
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 - Sep 23rd, 2025 5:40 am
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease - Sep 18th, 2025 5:41 am
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation - Sep 4th, 2025 6:00 am
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update - Aug 12th, 2025 5:00 am
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference - Jul 24th, 2025 6:53 am
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering - Jul 16th, 2025 7:03 am
Gain Therapeutics Announces Proposed Public Offering - Jul 15th, 2025 2:36 pm